吉非替尼治疗非小细胞肺癌疗效的Meta分析
Meta analysis of curative effect of gefitinib in the treatment of non-small cell lung cancer
宋燕峰 1李宝福 1曹洁2
作者信息
- 1. 天津市咸水沽医院 内科,天津 300350
- 2. 天津医科大学总医院 呼吸科,天津 300000
- 折叠
摘要
目的 全方位评价靶向治疗非小细胞肺癌的安全性和有效性.方法 计算机检索国内外数据网,检索时限为2009~2013年,收集不同治疗方法对非小细胞肺癌的疗效.按照纳入与排除标准筛选文献、提取资料和数据分析后,采用Rev Man5.0软件进行Meta分析.结果 总共10个随机对照试验被纳入本分析,患者共806例.Meta分析结果显示:与传统化疗相比较疾病的完全缓解率(CR=1.93,95%CI:1.23-3.02,P=0.004)、疾病的客观有效率(RR=1.72,95%CI:1.24-2.39,P=0.001).上述数据差异均无统计学意义.副反应情况稳定,所出现的问题都在可控制范围内.结论 靶向治疗能够显著降低恶心呕吐以及肾功能损伤发生的风险,但腹泻、皮疹等副反应还没有显著改善.
Abstract
Objective To evaluate the safety and efficacy of targeted therapy for non - small cell lung cancer (NSCLC). Methods Computer retrieval data network at home and abroad, retrieval time limit from 2009 to 2013, collected the curative effect of different treatments on non-small cell lung cancer. According to include and exclude standard, after screening of literature and data analysis, extract data using Rev Man 5.0 software for Meta analysis. Results A total of ten randomized controlled trials were included in this analysis, with a total of 806 cases of patients. Meta analysis results show that compared with traditional chemotherapy complete response rate of the disease (CR = 1.93, 95% CI: 1.23-1.23, P = 0.004), disease objective efficient (RR = 1.72, 95% CI: 1.24-1.24, P = 0.001). The above data are statistically significant. Side effects in a stable condition, all the problems in the controllable range. Conclusion Targeted therapy can significantly reduce the risk of nausea and vomiting and kidney damage, but there is no significant side effects such as diarrhea, rashes.
关键词
靶向治疗/非小细胞肺癌/Meta分析Key words
targeted therapy/non-small cell lung cancer/Meta analysis引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据